Ark receives licence to manufacture first gene medicine for commercial supply

24-Oct-2005

Ark Therapeutics Group plc announced that, following an inspection by the Finnish National Agency for Medicines, on behalf of the European Medicines Agency (EMEA), its facility in Kuopio, Finland has received Good Manufacturing Practice (GMP) Certification to manufacture commercial supplies of its adenoviral-based gene medicine Cerepro(TM), a gene based medicine for the treatment of brain cancer.

Ark's facility, in Kuopio, Finland is believed to be the only facility outside of China to have been licensed to manufacture gene based medicines for commercial supply.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances